Lanes R, Plotnick L P, Lee P A
Pediatrics. 1979 May;63(5):731-5.
Previous studies have not clarified whether human growth hormone (HGH) therapy can significantly increase the height of patients with intrauterine growth retardation (IUGR). To determine whether the initial increase in growth rate is sustained through subsequent treatment, 19 prepubertal patients who had IUGR were treated with HGH. Ten of them received a second treatment course. Growth rates (in centimeters per year) were 4.8 +/- 1.4 (mean +/- SD) for the pretreatment period, 7.6 +/- 2.3 for the first treatment period, 4.2 +/- 2.5 for the interval between treatments, 5.9 +/- 1.4 for the second treatment period, and 4.3 +/- 2.6 for the posttreatment period. Growth rates for the two treatment periods were significantly greater than for the periods before, interval between, and posttreatment. Height expressed as the number of standard deviations below the mean for age increased significantly between the onset of treatment and the most recent measurement. These data indicate that HGH has a sustained positive effect on increasing growth rates in children with IUGR, although the magnitude of the effect may decrease with further treatment. Furthermore, we suggest that it is worthwhile to treat patients who have IUGR with HGH for prolonged periods of time, if supplies exceed those necessary to treat children with growth hormone deficiency.
以往的研究尚未阐明人类生长激素（HGH）疗法是否能显著提高宫内生长迟缓（IUGR）患者的身高。为了确定生长速率的初始增加在后续治疗中是否持续，对19例患有IUGR的青春期前患者进行了HGH治疗。其中10例接受了第二个疗程的治疗。治疗前期的生长速率（厘米/年）为4.8±1.4（平均值±标准差），第一个治疗期为7.6±2.3，治疗间隔期为4.2±2.5，第二个治疗期为5.9±1.4，治疗后期为4.3±2.6。两个治疗期的生长速率显著高于治疗前、治疗间隔期和治疗后期。以低于年龄均值的标准差数表示的身高在治疗开始至最近一次测量期间显著增加。这些数据表明，HGH对提高IUGR儿童的生长速率有持续的积极作用，尽管随着进一步治疗，这种作用的程度可能会降低。此外，我们建议，如果供应的药物超过治疗生长激素缺乏儿童所需的量，那么长期用HGH治疗IUGR患者是值得的。
